(±)-肾上腺素盐酸盐,(±)-Epinephrine hydrochloride;pharmaceutical secondary standard, certified reference material

别名:肾上腺素盐酸盐标准品;DL-肾上腺素盐酸盐;盐酸肾上腺素;消旋肾上腺素;4-(1-羟基-2-[甲氨基]乙基)-1,2-苯二醇 盐酸盐; (±)-Adrenalin, 4-(1-Hydroxy-2-[methylamino]ethyl)-1,2-benzenediol hydrochloride

Empirical Formula (Hill Notation): C9H13NO3 · HCl CAS号: 329-63-5 分子量: 219.67 MDL编号: MFCD00050562
货号(SKU): PHR3234
CAS号: 329-63-5
MDL号: MFCD00050562
签订合同 √ 正规发票 √ 技术支持 √ 质量保障 √ 全程可追溯 √
¥2,170.00

说明

一般描述

Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
 

生化/生理作用

肾上腺素能受体激动剂。
 

分析说明

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
 

其他说明

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
 

附注

To see an example of a Certificate of Analysis for this material enter LRAA6959(changes by product) in the Documents slot below. This is an example certificate only and may not be the lot that you receive.
 
 

属性

等级

certified reference material
pharmaceutical secondary standard

质量水平

CofA

current certificate can be downloaded

包装

pkg of 50 mg

application(s)

pharmaceutical

储存温度

2-8°C

SMILES string

OC(CNC)C1=CC=C(O)C(O)=C1.Cl

InChI

1S/C9H13NO3.ClH/c1-10-5-9(13)6-2-3-7(11)8(12)4-6;/h2-4,9-13H,5H2,1H3;1H

InChI key

ATADHKWKHYVBTJ-UHFFFAOYSA-N

 

安全信息

象形图

Skull and crossbones

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

个人防护装备

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

商品规格
属性名称属性值
储存温度 Storage temp.2-8°C冷藏
全球实时库存 Availability √美国St. Louis ≥ 20 | 欧洲Eur. ≥ 16 | 東京Tokyo ≥ 5 | 香港与北京 ≥ 20